Checking frailty to guide treatment in older blood cancer patients
Part of Blood & lymphatic, Cancer clinical trials.
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 60 years old or older
- Have (or might have) a blood cancer such as acute leukemia or MDS
- Be willing and able to sign consent to join the study
- If you’re in the transplant/CAR T group: plan to get an allogeneic blood or marrow transplant
- If you’re in the transplant/CAR T group: plan to get CAR T-cell therapy (a treatment using your immune cells)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
This study evaluates how to better assess and manage frailty (age-related weakness and vulnerability) in older cancer patients aged 70 and up who are starting chemotherapy or other cancer treatments. The goal is to help doctors tailor treatment plans to each patient's individual strength and health status.
This study tests an investigational treatment made from special cells (called mesenchymal stromal cells) that might help reduce frailty in older adults. The treatment is given through an IV and aims to improve strength and overall function.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.